You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, February 2014
|
| DOI | 10.1186/alzrt238 |
| Pubmed ID | |
| Authors |
Haakon B Nygaard, Christopher H van Dyck, Stephen M Strittmatter |
| Abstract |
Alzheimer's disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug design based on distinct signaling pathways in this disorder is only now emerging. Here we review the putative signaling pathway of amyloid-beta (Aβ), by which the tyrosine kinase Fyn is activated via cell surface binding of Aβ oligomers to cellular prion protein. Several lines of evidence implicate Fyn in the pathogenesis of AD, and its interaction with both Aβ and Tau renders Fyn a unique therapeutic target that addresses both of the major pathologic hallmarks of AD. We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD. The results of this trial and a planned phase IIa multisite study will provide important data regarding the potential for this therapeutic strategy in AD. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 214 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| United Kingdom | 1 | <1% |
| Hungary | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 209 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 50 | 23% |
| Student > Bachelor | 33 | 15% |
| Researcher | 27 | 13% |
| Student > Master | 21 | 10% |
| Student > Doctoral Student | 11 | 5% |
| Other | 31 | 14% |
| Unknown | 41 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 43 | 20% |
| Biochemistry, Genetics and Molecular Biology | 40 | 19% |
| Neuroscience | 30 | 14% |
| Medicine and Dentistry | 19 | 9% |
| Chemistry | 14 | 7% |
| Other | 25 | 12% |
| Unknown | 43 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 158. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2023.
All research outputs
#258,619
of 25,374,917 outputs
Outputs from Alzheimer's Research & Therapy
#39
of 1,465 outputs
Outputs of similar age
#2,391
of 322,641 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 12 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,465 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,641 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.